ABSTRACT
Chimeric antigen receptor-expressing T (CAR-T) cells induce robust antitumor responses in patients with hematologic malignancies. However, CAR-T cells exhibit only limited efficacy against solid tumors such as hepatocellular carcinoma (HCC), partially due to their limited expansion and persistence. CD8+ T cells, as key components of the adaptive immune response, play a central role in antitumor immunity. Aerobic glycolysis is the main metabolic feature of activated CD8+ T cells. In the tumor microenvironment, however, the uptake of large amounts of glucose by tumor cells and other immunosuppressive cells can impair the activation of T cells. Only when tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment have a glycolytic advantage might the effector function of T cells be activated. Glucose transporter type 1 (GLUT1) and acylglycerol kinase (AGK) can boost glycolytic metabolism and activate the effector function of CD8+ T cells, respectively. In this study, we generated GPC3-targeted CAR-T cells overexpressing GLUT1 or AGK for the treatment of HCC. GPC3-targeted CAR-T cells overexpressing GLUT1 or AGK specifically and effectively lysed GPC3-positive tumor cells in vitro in an antigen-dependent manner. Furthermore, GLUT1 or AGK overexpression protected CAR-T cells from apoptosis during repeated exposures to tumor cells. Compared with second-generation CAR-T cells, GPC3-targeted CAR-T cells overexpressing GLUT1 or AGK exhibited greater CD8+ T-cell persistence in vivo and better antitumor effects in HCC allograft mouse models. Finally, we revealed that GLUT1 or AGK maintained anti-apoptosis ability in CD8+ T cells via activation of the PI3K/Akt pathway. This finding might identify a therapeutic strategy for advanced HCC.
Subject(s)
Carcinoma, Hepatocellular , Glucose Transporter Type 1 , Glypicans , Liver Neoplasms , Carcinoma, Hepatocellular/therapy , Carcinoma, Hepatocellular/immunology , Carcinoma, Hepatocellular/metabolism , Animals , Liver Neoplasms/immunology , Liver Neoplasms/therapy , Liver Neoplasms/pathology , Glucose Transporter Type 1/metabolism , Humans , Mice , Glypicans/metabolism , Glypicans/immunology , Immunotherapy, Adoptive/methods , Cell Line, Tumor , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Receptors, Chimeric Antigen/immunology , Receptors, Chimeric Antigen/metabolism , Tumor Microenvironment , ApoptosisABSTRACT
Living tumors are of great scientific value for clinical medicine and basic research, especially for drug testing. An increasing number of drug tests fail due to the use of imperfect models. The aim of the present study was to develop a novel method combining vitrificationbased cryopreservation of tumor biopsies and precisioncut slice cultivation for the assessment of anticancer drug responses. Biological characteristics of rectal cancer liver metastasis biopsies could be retained by vitrificationbased cryopreservation. The patientderived xenograft models were successfully established using both fresh and warmed biopsy tissues. Precisioncut slicing provided a similar threedimensional architecture and heterogeneity to the original tumor. The positive drug responses in the xenograft model were consistent with those in precisioncut slice cultures in vitro. The present study demonstrated that live tumor biopsies could be preserved using vitrificationbased cryopreservation. The warmed tissues developed xenograft tumors, which were also useful for either in vivo or in vitro anticancer drug testing. Precisioncut slices derived from the warmed tissues provided an efficient tool to assess anticancer drug response in vitro.
Subject(s)
Antineoplastic Agents/therapeutic use , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Rectal Neoplasms/drug therapy , Rectal Neoplasms/pathology , Tissue Culture Techniques/methods , Animals , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Biopsy , Cryopreservation , Female , Humans , Liver Neoplasms/secondary , Male , Mice , Middle Aged , Treatment Outcome , Vitrification , Xenograft Model Antitumor AssaysABSTRACT
Highly effective targeted tumor recognition via vectors is crucial for cancer detection. In contrast to antibodies and proteins, peptides are direct targeting ligands with a low molecular weight. In the present study, a peptide magnetic nanovector platform containing a lipid bilayer was designed using a peptide amphiphile (PA) as a skeleton material in a controlled manner without surface modification. Fluorescein isothiocyanate-labeled epidermal growth factor receptor (EGFR) peptide nanoparticles (NPs) could specifically bind to EGFR-positive liver tumor cells. EGFR peptide magnetic vesicles (EPMVs) could efficiently recognize and separate hepatoma carcinoma cells from cell solutions and treated blood samples (ratio of magnetic EPMVs versus anti-EpCAM NPs: 3.5 ± 0.29). Analysis of the circulating tumor cell (CTC) count in blood samples from 32 patients with liver cancer showed that EPMVs could be effectively applied for CTC capture. Thus, this nanoscale, targeted cargo-packaging technology may be useful for designing cancer diagnostic systems.
Subject(s)
Cell Separation/methods , ErbB Receptors/metabolism , Liver Neoplasms/pathology , Neoplastic Cells, Circulating/pathology , Peptides/metabolism , Cell Line, Tumor , Humans , Lipid Bilayers/metabolism , Liver Neoplasms/blood , Magnets/chemistry , Nanocapsules/chemistry , Neoplastic Cells, Circulating/metabolismABSTRACT
BACKGROUND: Angiogenesis, the growth of new blood vessels, plays an important role in tumor growth and metastasis. Both cetuximab and endostatin have been found to reduce the expression of endothelial-stimulating growth factors such as vascular endothelial growth factor (VEGF) and interleukin (IL)-8. However, the effects of cetuximab alone or in combination with endostatin on human lung adenocarcinoma cell growth remain unclear. OBJECTIVE: The aim of this study was to evaluate the cellular and molecular effects of cetuximab alone and in combination with endostatin on human lung adenocarcinoma cell lines HI 299, SPC-A1, and H460 in vitro. Methods The epidermal growth factor receptor (EGFR) status of a panel of human lung adenocarcinoma cell lines was characterized using Western blot analysis. We used a modified tetrazolium salt assay to evaluate the growth-inhibitory effects of cetuximab and endostatin alone and in combination on the cell lines. We also determined the effects of these 2 drugs on VEGF and IL-8 expression using enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. Cells were treated for 4 days with cetuximab 12.5 µ/mL, endostatin 25 µ/mL, or cetuximab 12.5 µg/mL + endostatin 25 µg/mL. Untreated cells cultured for 4 days served as controls. RESULTS: EGFR expression in the H1299 cells was higher than in the SPC-A1 and H460 cells. Varying concentrations of cetuximab alone were associated with a significant growth-inhibitory effect on all 3 cell lines in a dose-dependent manner after 4 days of exposure compared with controls (all, P < 0.05). Compared with controls, varying concentrations of endostatin alone were not associated with significant inhibition of cell growth in any of the 3 cell lines. The inhibitory ratio of cetuximab + endostatin at varying concentrations was significantly greater than that of cetuximab alone (all, P < 0.05). On ELISA, either drug alone was associated with significant reductions in secreted VEGF and IL-8 in the HI 299, SPC-A1, and H460 cell lines (all, P < 0.05), with the exception of IL-8 concentration in the H460 cells. Mean (SD) VEGF expression with combination treatment in the H1299 and SPC-A1 cell lines (687 [21] and 629 [23] pg/mL, respectively) was significantly lower than with cetuxi-mab alone (878 [31] and 708 [20] pg/mL; both, P < 0.001); in the H460 cell line, combination treatment was not associated with a significant further reduction in VEGF expression. IL-8 concentrations with cetuximab in the H1299, SPC-A1, and H460 cell lines were 628 (20), 484 (29), and 532 (28) pg/mL, respectively, while the IL-8 concentrations with the combination treatment were 516 (20), 480 (18), and 467 (30) pg/mL. An enhanced effect of endostatin on IL-8 was observed in the H1299 and H460 cell lines (P < 0.001 and P = 0.018, respectively); however, no enhanced effect in the SPC-A1 line was observed. Similar results for VEGF and IL-8 expression were found using Western blot analysis. CONCLUSIONS: The results from this in vitro study suggest that cetuximab treatment might both inhibit human lung adenocarcinoma cell line growth and reduce the expression of VEGF and IL-8, which are the biomarkers of angiogenesis. Endostatin was not associated with inhibition of human lung adenocarcinoma cell line growth directly. Findings with the combination of cetuximab + endostatin suggest that endostatin might enhance the antiangiogenic and antitumor activity of cetuximab through an apparent effect on VEGF expression and, to a lesser degree, on IL-8 expression.
ABSTRACT
AIM: To express capsid tail protein P11 of T7 bacteriophage and produce mouse monoclonal antibody(mAb) against the protein. METHODS: P11 protein was cloned and recombinant P11 protein was expressed as a fusion protein with an N-terminal 6-His tag. The purified protein was used to immunize BALB/c mouse. The specificity of mAb was analyzed by ELISA and Western blot. RESULTS: P11 protein was successfully expressed and purified. SDS-PAGE analysis showed that the molecular weight of the expressed protein was approximately 27 kd. One hybridoma cell (2G11) secreting mAb against P11 was developed. The isotype of the mAb was IgG(2b). ELISA detection showed that titers of mAb was 1:8. 1 x 10(5) in ascites.Western blot analysis proved mAb obtained could react specifically to the recombinant p11 protein. CONCLUSION: Recombinant P11 protein and mAbs were successfully prepared.
Subject(s)
Antibodies, Monoclonal , Bacteriophage T7/chemistry , Capsid Proteins/immunology , Immunoglobulin G/immunology , Animals , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/isolation & purification , Bacteriophage T7/genetics , Cell Fusion , Cell Line, Tumor , Enzyme-Linked Immunosorbent Assay , Escherichia coli/genetics , Genetic Vectors , Hybridomas/immunology , Mice , Mice, Inbred BALB C , Viral Proteins/isolation & purificationABSTRACT
AIM: To develop an efficient RNA interference system using phagemid particles displaying the epidermal growth factor (EGF) ligand. METHODS: pSilencer1.0-siEGFP and pSilencer4.1-siAkt plasmids were constructed by gene clone technology. The modified helper phage genome (plasmid) M13KO7EGFCT was used to package phagemids, such as pSilencer1.0-siEGFP and pSilencer4.1-siAkt. ELISA was used to quantify the titer of the progeny virus particles. Single-strand DNA was extracted and analyzed by agarose gel electrophoresis to evaluate the percentage of the phagemid particles. The expression level of the reporter gene enhanced green fluorescence protein (EGFP) was determined by transducing phagemid particles packaging pSilencer1.0-siEGFP into cells. The level of Akt gene expression in cells transduced phagemid particles packaging pSilencer4.1-siAkt was examined by Western blotting. Hydroxycamptothecin (HCPT) was used to enhance the gene transduction efficiency. RESULTS: RNAi vectors pSilencer1.0-siEGFP and pSilencer4.1-siAkt were successfully constructed. Phagemid-encoding siRNA can be packaged efficiently. After the cells were infected by EGF displaying phagemid particles in the presence of HCPT, the expression of the target gene EGFP or Akt was substantially downregulated. CONCLUSION: Cell-targeted phagemid particles are efficient siRNA delivery vectors in the presence of HCPT.
Subject(s)
Gene Transfer Techniques , Genetic Vectors , Plasmids , RNA Interference , Antineoplastic Agents, Phytogenic/pharmacology , Bacteriophages/genetics , Camptothecin/analogs & derivatives , Camptothecin/pharmacology , Cell Line, Tumor , Epidermal Growth Factor/genetics , Escherichia coli/genetics , Genes, Reporter , Green Fluorescent Proteins/metabolism , Humans , Ligands , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , RNA, Small Interfering/metabolism , Transduction, GeneticABSTRACT
AIM: To establish a cell line stably expressing EGFRvIIIex (epidermal growth factor receptor variant III extracellular domain) and evaluate its immunogenicity. METHODS: NIH3T3 cells stably expressing EGFRvIIIex was obtained by screening NIH3T3 cells transfected with pLNCX2-EGFRvIIIex, a plasmid encoding EGFRvIIIex. The expression level of EGFRvIIIex was examined by immunohistochemical staining and Western blot. The cell clone with the highest expression of EGFRvIIIex named as 3T3-vIIIex was used to immunize BALB/c mice. The titer and specificity of murine antiserum was evaluated by ELISA, Western blot and immunofluorescent staining. RESULTS: A NIN3T3 stable cell line with high EGFRvIIIex expression was obtained. The titer of the antiserum against human EGFRvIIIex was about 10(-5). Western blot and immunofluorescent staining analysis revealed the high specificity of the antiserum. CONCLUSION: High titer of antiserum against EGFRvIIIex can be obtained by NIH3T3 cell lines stably expressing EGFRvIIIex.
Subject(s)
ErbB Receptors/genetics , NIH 3T3 Cells/immunology , NIH 3T3 Cells/metabolism , Animals , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , Immune Sera/immunology , Immunohistochemistry , Mice , Mice, Inbred BALB C , Plasmids/genetics , TransfectionABSTRACT
AIM: To develop a simple method for monitoring protein localization of epidermal growth factor (EGF) in living cells. METHODS: Enhanced green fluorescent protein (EGFP) was used as an autofluorescent tag to label EGF ligands. SDS-PAGE and Western blot analysis were used to detect the expression of the EGFP-tagged EGF (EGFP-EGF) protein. The cell-binding and internalization activity of EGFP-EGF were analyzed by fluorescence-activated cell sorting (FACS) and confocal microscopy. RESULTS: EGFP-EGF protein was expressed in Escherichia coli and purified. A cell-binding assay demonstrated that the EGFP-EGF protein could bind efficiently to the cells expressing EGFR. The binding and internalization of EGFP-EGF can be visualized even at a very low concentration under confocal microscopy. The FACS-based assay for internalization activity indicated the accumulation of internalized EGFP-EGF over time. Furthermore, the results of the competition assay indicated its EGFR binding specificity. Using such a method, it does not need to label EGF with chemicals and avoid light in the experimental process. CONCLUSION: The fusion protein EGFP-EGF has several characters including high sensitivity, stability and convenience for manipulation, and is a powerful tool for the study of EGF endocytosis.
Subject(s)
Endocytosis , Epidermal Growth Factor/metabolism , Green Fluorescent Proteins/metabolism , Binding, Competitive , Blotting, Western , Epidermal Growth Factor/genetics , Escherichia coli/genetics , Escherichia coli/metabolism , Flow Cytometry , Green Fluorescent Proteins/genetics , HeLa Cells , Humans , Microscopy, Confocal , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/metabolismABSTRACT
To improve the targeting of adenovirus vector for gene therapy, a fusion gene sCAR-EGF, in which epidermal growth factor gene was fused to the 3' end of extracellular Coxsackie virus-adenovirus receptor gene, was constructed and cloned into shuttle plasmid pDC315 to obtain a recombinant plasmid pDC315-sCAR-EGF. With the AdMax system, AD-293 cells were co-transfected with pDC315-sCAR-EGF and adenovirus genomic plasmid pBHGloxdeltaE13cre. Through high efficiency site specific recombination, a replication-defective adenovirus Ad5-CMV-sCAR-EGF was constructed. The recombinant adenovirus was analyzed by PCR and Western blotting, the results indicated that Ad5-CMV-sCAR-EGF contained the fusion gene sCAR-EGF, and the adenovirus infected cells was induced to produce and secrete the fusion protein into the supernatant. We have demonstrated that the fusion protein sCAR-EGF is helpful for elevating the infection efficiency of Ad5-CMV-luc with the reporter gene in vitro, which providing a new approach to the gene therapy for tumors overexpressing EGFR.